Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: HIV Infection

In brief

The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.

Key facts

Study ID
NCT00249106
Run by
International AIDS Vaccine Initiative
People needed
45
Starts
2003-12-01
Expected to finish
2005-10-01
Last updated by the study team
2013-02-11

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.